Ongoing, recruitingTherapeutic confirmatory (Phase III)Interventional

CMV preemptive therapy in high-risk immunocompetent major heart surgery patients. A multicenter, double blind, randomized, clinical trial (GAN-CAR).

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic confirmatory (Phase III)

Sponsor

Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon

Enrolment target

226

Start

10 Jan 2023

Cytomegalovirus in high-risk immunocompetent major heart surgery.

What is this study about?

Number of days of good outcome during the 30 days follow-up. A good outcome implies that the patient is alive, out of the ICU, with no systemic antimicrobials, no mechanical ventilation, and no SAEs.

Who may be eligible?

Age 18 Years to any · Sex: All

Locations (1)

—
Spain

How to find out more

Official trial record

Always speak to your GP or specialist before deciding to take part in a study.